2019 年第 1 期 第 14 卷

伊立替康联合替吉奥与mFOLFIRI方案对晚期胃癌患者二线化疗的效果比较

Effects of irinotecan combined with tegafur and mFOLFIRI second-line chemotherapy on patients with advanced gastric cancer

作者：马丽华钱屹崟符炜夏开建陆晓

英文作者：

单位：215500江苏省常熟市第一人民医院苏州大学附属常熟医院肿瘤科

英文单位：

关键词：胃肿瘤；二线化疗；替吉奥；伊立替康；mFOLFIRI

英文关键词：

• 摘要：

• 【摘要】目的    探讨伊立替康联合替吉奥方案与mFOLFIRI方案对晚期胃癌患者的二线化疗效果。方法    选择2014年5月至2016年12月就诊于江苏省常熟市第一人民医院经一线治疗失败的进展期胃癌患者共58例，应用随机数字表法分为2组，对照组31例，观察组27例。观察组给予替吉奥联合伊立替康方案二线化疗，21 d为1个疗程,应用实体瘤疗效评价标准于2个疗程后进行疗效评价；对照组给予伊立替康+亚叶酸钙注射液+5-氟尿嘧啶的mFOLFIRI方案化疗，14 d为1个周期，2个周期为1个疗程，3个周期后进行疗效评价。比较2组患者无进展生存时间、总生存时间和不良反应发生率。结果    58例患者均可评价疗效，观察组疾病进展率低于对照组［33.3%(9/27)比45.2%（14/31）］，疾病控制率高于对照组［66.7%(18/27)比54.8%（17/31）］，差异均有统计学意义（均P<0.05）。观察组和对照组患者无进展生存时间分别为1.4~8.2和1.4~7.6个月，中位无进展生存时间分别为4.2和3.5个月，差异有统计学意义（P=0.026）。2组患者中位总生存时间比较差异无统计学意义（P=0.456）。观察组 Ⅲ~Ⅳ 度白细胞减少、中性粒细胞减少发生率均低于对照组，Ⅰ~Ⅳ 度贫血、呕吐、乏力、口腔黏膜炎发生率低于对照组，差异均有统计学意义（均P<0.05）。结论    与mFOLFIRI方案相比，伊立替康联合替吉奥方案二线治疗晚期胃癌可提高患者的疾病控制率及无进展生存时间，同时减轻不良反应，患者耐受性更好，但不能改善患者的有效率和总生存时间。

• 【Abstract】Objective    To investigate the effects of irinotecan combined with tegafur and mFOLFIRI second-line chemotherapy on patients with advanced gastric cancer. Methods    From May 2014 to December 2016, 58 patients with advanced gastric cancer who failed in first-line chemotherapy were enrolled at Changshu No.1 People′s Hospital. They were randomly divided into control group（n＝31） and observation group（n＝27）. The observation group was treated with irinotecan plus tegafur second-line chemotherapy; 1 course was 21 d; the efficacy was assessed according to Response Evaluation Criteria in Solid Tumors after 2 courses of therapy. The control group had mFOLFIRI second-line chemotherapy（irinotecan+calcium folinate+5-fluorouracil）; 1 cycle was 14 d; 1 course was 2 circles; the efficacy was assessed after 3 circles. Progression free survival(PFS), overall survival(OS) and adverse reactions were analyzed. Results    Disease progression rate in the observation group was lower than that in the control group［33.3%(9/27) vs 45.2%（14/31）］(P<0.05). Disease control rate in the observation group was higher than that in the control group［66.7%(18/27) vs 54.8%（17/31）］(P<0.05). PFS time was 1.4-8.2 months in the observation group and 1.4-7.6 months in the control group was; the median PFS time was 4.2 and 3.5 months respectively; there was a significant difference between the two groups(P=0.026). OS showed no significant difference between the two groups（P=0.456）. Incidences of grade Ⅲ-Ⅳ leukopenia and neutropenia in the observation group were lower than those in the control group; incidences of grade Ⅰ-Ⅳ anemia, vomiting, fatigue and mucositis in the observation group were lower than those in the control group(all P<0.05). Conclusions    Compared with mFOLFIRI regimen, irinotecan plus tegafur second-line chemotherapyis more effective in improving disease control rate and PFS with less adverse reaction and better tolerance; it shows no positive effect on the total therapeutic rate and OS.